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1. Introduction 
The term antibiotic associated diarrhea is usually reserved for diarrhea caused by infection 
with the organism Clostridia Difficile. Infection is thought to take place after the normal 
intestinal flora is altered by antibiotic use allowing for proliferation of Clostridia Difficile. 
Worryingly, the incidence and severity of illness caused by Clostridia Difficile is on the 
increase. 
2. Pathophysiology 
Clostridia difficile is a gram positive, spore forming anaerobic bacilli1 Infection occurs when 
the organism is ingested. Though initially thought of as a nosocomial infection, community 
acquired clostridia difficile infection is increasingly recognized.2  
Clostridia Difficile produces a variety of toxins, toxin A (enterotoxin) and B (cytotoxin) are 
the toxins most frequently linked to disease. They cause inflammation and disrupt cell 
cytoskeleton synthesis leading to colonic cell disruption.3,4,5 A new strain, termed NAP1 or 
BI or 027 (depending on the technique used to identify it) was identified in the early 2000s 
the cause of selected outbreaks. This strain of clostridia difficile is associated with clinically 
more severe disease, innate resistance to quinolones and higher amounts of toxin 
production.6 
3. Epidemiology 
Clostridia difficile infection was linked to the development of pseudomembranous colitis in 
the 70’s.7 Initial cases were mostly linked to clindamycin but since then the range antibiotics 
linked with development of Clostridia Difficile has widened and cephalosporins and 
floroquinolones are thought to be the major causes.8 
Though less often thought of as a cause of diarrhea in developing countries, pathogenic C. 
Difficile has been noted in South Africa9 and India.10 
The incidence rate of C. Difficile infection in the US was about 30 to 40 cases per hundred 
thousand.11  
One research group noted an increasing rate of colectomies following C. Difficile infection.12  
Canadian authors noted a four fold increase in background prevalence of C. Difficile 
between when the period before 2002 was compared to 2003.13 
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4. Clinical presentation 
Presentation may range from asymptomatic carrier state14 to fulminant colitis.15 
Symptomatic patients typically present with watery diarrhea and lower abdominal pain.16 
Severe diarrhea with leucocytosis, fever, abdominal pain and distention occurs in the 
severely ill16,17. Surgical management with colectomy may be required in severe cases18. C. 
Difficile colitis was increasingly listed as the cause of death in an English population.19 
Rises in white cell count to above 30,000 or a doubling of serum creatinine have been 
suggested as harbingers complicated disease.20 
5. Diagnosis 
C. Difficile diagnosis is usually done with laboratory testing in a patient suspected to be 
having the infection. 
One of the most sensitive and specific tests available is the cell cytotoxycity assay, which 
had a sensitivity of 98% and specificity of 99% when compared to clinical and laboratory 
criteria.21 This test is unfortunately technically demanding and may not be the first choice of 
many laboratories.  
Many laboratories will use EIAs for detection of toxin A and B. These tests are insensitive 
when compared to cell culture or cytotoxicity assay but they are cheaper and produce 
results in hours rather than days.22 Due to the lower positive predictive value of these tests a 
2 step approach with a sensitive screening test followed by confirmation by culture or cell 
cytotoxicity may be appropriate.23 
Testing for glutamate dehydrogenase, an enzyme produced by C. Difficile is sensitive (96 to 
100%) 24, cheap, and rapid but it only detects presence of organism rather than toxin 
production. 
Though its usually unnecessary, direct visualization of colitis by endoscopy is virtually 
diagnostic as they are few other infections that would cause pseudomembrane formation.25 
Endoscopy carries the risk of perforation in fulminant colitis. 
6. Treatment 
First line therapy for C. Difficile infection has long been considered to be a choice between 
metronidazole or vancomycin. Resolution of disease was seen in over 90% of patients taking 
a 10 day course of either therapy.26  
More recently, metronidazole has been associated with therapeutic failure rates as high as 50 
percent if persistence of disease and recurrence are conbined.27 That said, oral 
metronidazole at a dose of 500mg, three times daily for ten to fourteen days remains the 
initial recommended therapy for mild disease.28 Oral or rectal vancomycin (500mg four 
times a day) is recommended for more severe disease.28 Patients who cannot tolerate oral 
therapy may be treated with intravenous metronidazole.29  
Up to 25% of patients may have recurrent infection16 believed to occur because of 
germination of spores or ingestion of new spores.  
Many approaches have been taken to recurrent symptomatic C Difficile infection. A tapered 
or pulsed course of oral vancomycin may reduce recurrence rates30. 
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Other approaches include fecal transplants31, immunization against C difficile toxins32, 
cholestyramine33, rifampin34 or probiotics35. There isn’t sufficient data to recommend any of 
these approaches.  
Recently fidaxomicin (200 mg oral, twice daily for ten days), a macrolide antibiotic, was 
shown to be non inferior to vancomycin.36 During the trial referenced, patients were noted 
to have a lower recurrence rate when they were treated using fidaxomicin rather than 
vancomycin (13.3% vs. 24.0%) 
7. Prevention 
Judicious use of antibiotics has been shown to reduce the rates of C. difficile infection.37, 38 
Washing hands with soap and water, using gloves when touching patients and use of 
disposable thermometers have been recommended as control measures with good quality 
evidence of efficacy.39 Alcohol hand washing gels are not effective in preventing disease 
spread.40 
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